



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

the world would like to see. As countries discharge their responsibility to protect vulnerable individuals in their populations, they must ensure adequate supply to other countries. Global policy must weigh the risks of adopting booster doses ad libitum across the world at this stage of the pandemic.

I declare no competing interests.

K Srinath Reddy

ksrinath.reddy@phfi.org

Public Health Foundation of India, Gurugram 122002, India

- Center for Disease Control and Prevention. Vaccine breakthrough infections: the possibility of getting COVID-19 after getting vaccinated. Sept 7, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html> (accessed Oct 5, 2021).
- Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J Med* 2021; published online Oct 6. <https://doi.org/10.1056/NEJMoa2114114>.
- Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. *N Engl J Med* 2021; published online Oct 6. <https://doi.org/10.1056/NEJMoa2114583>.
- Burger L, Shabong Y. EU regulator backs mRNA vaccine booster for people with weak immunity. Oct 4, 2021. <https://www.reuters.com/world/europe/eu-says-mrna-vaccine-booster-may-be-given-those-with-weak-immunity-2021-10-04/> (accessed Oct 6, 2021).
- Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune responses. *Lancet* 2021; **398**: 1377–80.
- Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet* 2021; published online Oct 29. [https://doi.org/10.1016/S0140-6736\(21\)02249-2](https://doi.org/10.1016/S0140-6736(21)02249-2).
- Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**: 1337–43.
- Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021; **398**: 1407–16.
- Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. *N Engl J Med* 2021; published online Oct 6. <https://doi.org/10.1056/NEJMoa2109730>.
- Cines DB, Bussell JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. *N Engl J Med* 2021; **384**: 2254–56.
- WHO. Vaccine equity. <https://www.who.int/campaigns/vaccine-equity> (accessed Oct 4, 2021).

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID



The scale of chronic ill health and disability after COVID-19 has been described as the next big global health challenge.¹ Prevalence estimates of a post-COVID-19 condition, long COVID, or post-acute sequelae of SARS-CoV-2 vary according to definition, methodology, and population. A recent systematic review reported persistent symptoms at 3–6 months in a median of 57% (range 13–92) of hospitalised patients (six studies) and 26% (2–62) of non-hospitalised patients (ten studies).² This study and other reviews identified few studies from low-income settings,³ but with more than 245 million SARS-CoV-2 infections reported globally,⁴ millions of people are likely to already be experiencing long-term illness. While COVID-19 vaccines have reduced the risk of severe COVID-19 and death, continued high rates of SARS-CoV-2 infection will lead to further disability, having a huge impact on individuals, their families, health services, and society.

Patients coined the unifying term long COVID,⁵ but there is not yet a health professional consensus definition or nomenclature. In October, 2021, WHO used a Delphi method to develop a clinical definition of post-COVID-19 condition as a range of symptoms

occurring 3 or more months after probable or confirmed SARS-CoV-2 infection that last for at least 2 months, cannot be explained by an alternative diagnosis, generally have an impact on daily functioning, and may fluctuate or relapse over time.⁶ A separate definition is recommended for children.⁶ Other definitions use different time frames and terminology,^{7,8} but remain difficult to apply in research and clinical management.

Published Online
November 10, 2021
[https://doi.org/10.1016/S0140-6736\(21\)02444-2](https://doi.org/10.1016/S0140-6736(21)02444-2)



Long COVID has many characteristic symptoms, including post-exertional symptom exacerbation, severe fatigue, breathlessness, tachycardia, cognitive deficits, and dysautonomia.^{9,10} However, the absence of specific diagnostic criteria means that clinicians and patients must live with substantial uncertainty, with the risk that people will be either overinvestigated and overtreated or not receive adequate support.¹¹

A hidden epidemic of long COVID is possible given the challenges in access to care and uncertainty about diagnostic criteria—factors that will differ in their importance between low-income and high-income settings.¹² Patients report not being taken seriously by medical practitioners or refused referral to long COVID services.^{5,13} These services remain limited and where they exist vary in scope, quality, and access to some therapeutic options. In the absence of diagnostic tests, long COVID is partly a diagnosis of exclusion, creating challenges for patients and carers. Previous diagnoses of exclusion, such as chronic fatigue syndrome, fibromyalgia, and irritable bowel syndrome, are now better defined than in the past, meaning patients are more able to obtain acknowledgment, treatment, sick pay, or insurance.¹⁴

Data from high-income countries suggest that ongoing symptoms after acute COVID-19 can occur irrespective of initial disease severity and are more prevalent in women, middle-aged and older adults, people with pre-existing health conditions, and those admitted to hospital with acute COVID-19,¹⁵ although the latter might also reflect post-intensive care syndrome.¹⁶ However, the pathophysiology of long COVID remains poorly understood with different mechanisms probably explaining the heterogeneous symptoms, including viral persistence, autoimmunity due to molecular mimicry, aberrant T-cell and humoral responses, and micro-thrombi.¹⁷ Understanding the mechanisms and natural history of long COVID will inform diagnostic and therapeutic strategies, building on experience of other post-viral syndromes—eg, careful pacing in rehabilitation to avoid post-exertional symptom exacerbation. To date no antiviral or immunomodulatory drug has proven effective for the treatment of long COVID in trials. Some preliminary reports suggest COVID-19 vaccination might improve symptoms in some people,^{18,19} supporting the notion of a possible role for persistent

viral reservoirs, circulating virus fragments, or both in long COVID.¹⁹

The COVID-19 pandemic has shown the power and necessity of large-scale, multicentre, adaptive platform trials and applying these approaches to long COVID will help accelerate development of an evidence base for disease management. Importantly, these trials will need to include centres across various settings with different resource availabilities, such as in WHO's Solidarity and the Recovery and REMAP-CAP treatment trials. In the short term, it might be prudent to evaluate therapies for specific symptoms, such as cognitive dysfunction, breathlessness, and fatigue, rather than pursuing a single treatment for such a broadly defined syndrome, although patients would clearly welcome an effective general treatment.

Ideally, patients with this complex disease process which affects multiple systems should be assessed by a medical generalist with access to diagnostic tools and relevant multidisciplinary teams, but globally decentralised community services will be more sustainable in a COVID-19-endemic world. Robin Gorna and colleagues, writing as individuals with lived experience of long COVID, advise that "psychological aspects of disease should be managed as part of the recovery process, but not seen as the primary treatment focus for all".¹³ As with most chronic disease, a holistic approach and individualised rehabilitation plan will be crucial. Reliable online and other resources are needed to ensure that clinicians, researchers, and patients can keep up to date with the latest evidence on long COVID in a rapidly evolving field. Yet these resources will be beyond what is available in many health systems, particularly in low-income and middle-income countries (LMICs).

COVID-19 has exacerbated existing inequities and created new vulnerabilities, especially in low-resource settings, and long COVID is amplifying these disparities.²⁰ Countries with limited resources and already overwhelmed health systems are unlikely to be able to provide specific services for long COVID, which will therefore remain hidden. Surveillance of this emerging public health threat must be a priority globally, and we support the need for national registers, with chronic cases reported alongside infections, hospitalisations, and deaths. Large-scale multinational partnerships, including LMIC

For the WHO Solidarity trial see <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>
For the Recovery trial see <https://www.recoverytrial.net/>
For the REMAP-CAP trial see <https://www.remapcap.org/>

researchers, patients, and funding, are needed to evaluate evidence-based diagnostics and therapeutics and assure affordability, applicability, and adaptability to different health-care systems, including in resource-limited contexts.²¹ Such collaborative efforts should lead to greater understanding of disease mechanisms and treatments for long COVID, improving lived experience of the millions of people with this condition around the world.

HW reports grants from the UK Department of Health and Social Care (DHSC) for the REACT study, grants from DHSC/National Institute for Health Research (NIHR) for the REACT Long COVID study, and grants from the NIHR Imperial Biomedical Research Centre for the Patient Experience Research Centre.

PE reports grants from UK Research and Innovation (UKRI)/NIHR for REACT-Genomics England and REACT Long COVID studies. GC reports funding from NIHR, DHSC, and UKRI for REACT-Genomics England and REACT Long COVID studies. BF, PJG, SWXO, DMA, BD, and NS declare no competing interests.

**Helen Ward, Barnaby Flower, Patricia J Garcia, Sean Wei Xiang Ong, Daniel M Altmann, Brendan Delaney, Nikki Smith, Paul Elliott, Graham Cooke*
h.ward@imperial.ac.uk

School of Public Health (HW, PE), Department of Infectious Disease (BF, GC), Imperial College London, London W2 1PG, UK; School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru (PJG); National Centre for Infectious Diseases, Singapore (SWXO); Department of Immunology and Inflammation, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK (DMA); Department of Surgery and Cancer, Imperial College London, London, UK (BD); Patient Advisory Panel, REACT-Long Covid Study, Imperial College London, London, UK (NS)

- 1 Briggs A, Vassall A. Count the cost of disability caused by COVID-19. *Nature* 2021; **593**: 502–05.
- 2 Castanares-Zapatero D, Kohn L, Dauvrin M. Long COVID: pathophysiology—epidemiology and patient needs. Belgian Health Care Knowledge Centre, 2021. https://www.kce.fgov.be/sites/default/files/atoms/files/KCE_344_Long_Covid_scientific_report_1.pdf (accessed Nov 4, 2021).
- 3 Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Glob Health* 2021; **6**: e005427.
- 4 WHO. WHO coronavirus (COVID-19) dashboard. Nov 5, 2021. <https://covid19.who.int/> (accessed Nov 8, 2021).
- 5 Callard F, Perego E. How and why patients made Long Covid. *Soc Sci Med* 2021; **268**: 113426.
- 6 WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. Oct 6, 2021. Geneva: World Health Organization, 2021.
- 7 US Centers for Disease Control and Prevention. Post COVID conditions: information for healthcare providers. 2021. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html> (accessed Nov 4, 2021).
- 8 National Institute for Health and Care Excellence, Royal College of General Practitioners, Health Improvement Scotland. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline (NG188). London: National Institute for Health and Care Excellence, 2020.
- 9 Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. *Clin Auton Res* 2021; **31**: 365–68.
- 10 Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020; **100**: 327–32.
- 11 Lokugamage AU, Bowen MA, Blair J. Long covid: doctors must assess and investigate patients properly. *BMJ* 2020; **371**: m4583.
- 12 Walker AJ, MacKenna B, Inglesby P, et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. *Br J Gen Pract* 2021; **71**: e806–14.
- 13 Gorna R, MacDermott N, Rayner C, et al. Long COVID guidelines need to reflect lived experience. *Lancet* 2021; **397**: 455–57.
- 14 Dumit J. Illnesses you have to fight to get: facts as forces in uncertain, emergent illnesses. *Soc Sci Med* 2006; **62**: 577–90.
- 15 Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; **397**: 220–32.
- 16 Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). *Clin Rev Allergy Immunol* 2021; published online Feb 20. <https://doi.org/10.1007/s12016-021-08848-3>.
- 17 Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* 2021; **27**: 601–15.
- 18 Massey D, Berrent D, Akrami A, et al. Change in symptoms and immune response in people with post-acute sequelae of SARS-CoV-2 infection after SARS-CoV-2 vaccination. *medRxiv* 2021; published online July 28. <https://doi.org/10.1101/2021.07.21.21260391> (preprint).
- 19 Tran V-T, Perrodeau E, Saldanha J, et al. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-Cohort in France. *SSRN* 2021; published online Sept 29. <http://dx.doi.org/10.2139/ssrn.3932953> (preprint).
- 20 Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. *BMJ* 2021; **372**: n129.
- 21 COVID-19 Clinical Research Coalition. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *Lancet* 2020; **395**: 1322–25.